Acceleron Pharma
XLRN
XLRN was delisted on the 19th of November, 2021.
91 hedge funds and large institutions have $709M invested in Acceleron Pharma in 2014 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 40 increasing their positions, 19 reducing their positions, and 14 closing their positions.
1,035% more call options, than puts
Call options by funds: $3.36M | Put options by funds: $296K
111% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 19
93% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 14
19% more capital invested
Capital invested by funds: $593M → $709M (+$115M)
15% more funds holding
Funds holding: 79 → 91 (+12)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$70.7M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$47.7M |
| 3 |
QF
QVT Financial
New York
|
+$20M |
| 4 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$19.7M |
| 5 |
State Street
Boston,
Massachusetts
|
+$14.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$56.7M |
| 2 |
DVC
Deer VII & Co
Larchmont,
New York
|
-$31.1M |
| 3 |
PVMCI
Polaris Venture Management Co IV
Boston,
Massachusetts
|
-$17.2M |
| 4 |
ICAP
Independence Capital Asset Partners
Denver,
Colorado
|
-$4.04M |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
-$3.62M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
ARTA
101
A.R.T. Advisors
New York
| – | -$282K | -8,202 | Closed |
|
|
PC
102
Passport Capital
San Francisco,
California
| – | -$202K | -5,845 | Closed |
|
|
BJ
103
BlackRock Japan
Tokyo,
Japan
| – | -$175K | -5,082 | Closed |
|
|
SO
104
STRS Ohio
Columbus,
Ohio
| – | -$55K | -1,600 | Closed |
|
105
BNP Paribas Financial Markets
Paris,
France
| – | -$240 | -7 | Closed |
|
XLRN Hedge Fund Activity: Q2 2014 in Review
91 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Acceleron Pharma (XLRN) for Q2 2014, worth a combined $709M — up 19% from $593M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new XLRN positions and 14 closed out — a net gain of 13 holders — while 40 added to existing stakes and 19 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $70.7M. The largest seller was OrbiMed, cutting an estimated $56.7M.
- 91 institutional investors held Acceleron Pharma (XLRN) as of Q2 2014, up from 79 in Q1 2014.
- Funds reported $709M of Acceleron Pharma stock for Q2 2014, up 19% quarter-over-quarter.
- 27 funds opened new Acceleron Pharma positions in Q2 2014 and 14 closed out, a net change of +13 holders.
- The largest Acceleron Pharma buyer in Q2 2014 was Fidelity Investments, an estimated $70.7M added.
- The largest Acceleron Pharma seller in Q2 2014 was OrbiMed, an estimated $56.7M sold.
Based on aggregated 13F filings for Q2 2014.